Article Text

Download PDFPDF

Association of medication beliefs and self-efficacy with adherence in urban Hispanic and African–American rheumatoid arthritis patients
  1. Tanya M Spruill1,
  2. Gbenga Ogedegbe1,
  3. Leslie R Harrold2,
  4. Jeffrey Potter3,
  5. Jose U Scher3,
  6. Pamela B Rosenthal3,
  7. Jeffrey D Greenberg3
  1. 1 Department of Population Health, New York University School of Medicine, New York, New York, USA
  2. 2 Departments of Orthopedics and Physical Rehabilitation and Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA
  3. 3 Department of Medicine (Rheumatology), New York University School of Medicine, New York, New York, USA
  1. Correspondence to Dr Tanya M Spruill, Center for Healthful Behavior Change, Department of Population Health, New York University School of Medicine, 227 East 30th Street, 6th floor, Room 640, New York, NY 10016, USA; tanya.spruill{at}nyumc.org

Statistics from Altmetric.com

Adherence to rheumatoid arthritis (RA) medications varies widely but is frequently suboptimal1 and is particularly poor among racial/ethnic minority patients,2 which may help to explain the growing evidence of disparities in RA clinical outcomes.2 Beliefs about medications and self-efficacy perceptions (ie, confidence) regarding medication-taking behaviour are two modifiable patient factors that have been associated with adherence to RA medications in largely Caucasian study samples.1 Minority RA patients report more negative medication beliefs and lower self-efficacy compared with Caucasians,35 but to our knowledge, the relationship between these psychological factors and medication adherence in these groups has not been reported.

We addressed this question in a cross-sectional study of 56 urban Hispanic and African–American RA patients recruited consecutively from the waiting rooms of two NYU-affiliated rheumatology clinics in New York City (Bellevue Hospital and Hospital for Joint Diseases) between November 2012 and January 2013. All patients meeting the 1987 diagnostic criteria for RA who self-identified as Hispanic or African-American were eligible. Analysis of clinic registry data (N=231) revealed that patients who participated were similar to the overall Hispanic and African–American clinic populations with regard to age (p=0.40), gender (p=0.48), the proportion of Hispanic versus African–American patients (p=0.38) and disease activity (p=0.58). A research assistant administered the Morisky Medication Adherence Scale (MMAS)6, Beliefs about Medicines Questionnaire7 and an RA-adapted version of the Medication Adherence Self-Efficacy Scale8 via patient interviews. Demographic, disease and treatment variables were collected via patient interview, chart review and clinical assessment.

Sample characteristics are shown in table 1. Figure 1 shows the relationship between medication beliefs, self-efficacy (dichotomised using median splits) and medication adherence. Twice as many patients with high versus low medication concerns (66.7% vs 33.3%, χ2=5.53, p=0.02) and three times as many patients with low versus high self-efficacy (76.2% vs 23.8%, χ2=6.91, p=0.009) were classified as poor adherers (MMAS>2).6 Belief in the necessity of RA medications was high but was not significantly related to adherence (p=0.68). Among the set of potential covariates in table 1, only shorter disease duration and higher pain were associated with poorer adherence (p≤0.05). After adjustment for these covariates in a multivariable logistic regression analysis (N=50), higher medication concerns (p=0.04) and lower self-efficacy (p=0.007) each remained significantly and independently associated with poor medication adherence. Pain was marginally statistically significant in the multivariable model (p=0.08); disease duration was no longer significant (p=0.36).

Table 1

Sample characteristics

Figure 1

Rates of poor adherence by medication beliefs and self-efficacy (N=56). Medication beliefs and self-efficacy were each dichotomised using median splits. p values correspond to results of χ2 tests.

These findings are consistent with previous studies in predominantly Caucasian samples1 but to our knowledge, ours is the first study to document these relationships in Hispanic and African–American RA patients. Limitations of the present study include the cross-sectional design, small convenience sample and lack of objective adherence measures. Although the predictive validity of the MMAS has been demonstrated,6 the use of both RA therapies and painkillers complicates the assessment of adherence in this population. Larger studies are needed to confirm these findings and to explore the role of other possible contributors to poor adherence (eg, economic, cognitive, cultural, psychosocial factors). Still, the associations we observed are consistent with prior research in both non-minority RA samples1 and minority patients with other chronic diseases,9 ,10 and the magnitude of these associations increases our confidence in the results. Given the sample studied, the generalisability of these findings may be limited; the relationship between medication beliefs and self-efficacy with adherence in other minority groups both within and beyond the USA should be explored.

In conclusion, high medication concerns and low self-efficacy are associated with poor medication adherence in urban Hispanic and African–American RA patients, and are promising targets for interventions to improve adherence and health outcomes in this population.

Acknowledgments

The authors thank Lucy Alvarado for her assistance with recruitment and data collection.

References

Footnotes

  • Contributors TMS and JDG: study conception and design, data analysis and interpretation, drafting the article. GO, LRH and JP: data analysis and interpretation, critical revision of article. JS and PR: data acquisition and interpretation, critical revision of article. All authors gave final approval of the version to be published.

  • Funding This study was supported in part by grant UL1 TR000038 from the National Center for the Advancement of Translational Science (NCATS), National Institutes of Health.

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval NYU Institutional Review Board.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.